ICON Public Limited Company (IJF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ICON Public Limited Company (IJF) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€387.60 Million ≈ $453.15 Million USD) by net assets (€9.33 Billion ≈ $10.91 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of ICON Public Limited Company to measure how much of total assets are equity-financed.
ICON Public Limited Company - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how ICON Public Limited Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ICON Public Limited Company (IJF) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
ICON Public Limited Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ICON Public Limited Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INPOST S.A UNSP.ADR/1/2
F:6690
|
0.256x |
|
China Aerospace Times Electronics Co Ltd
SHG:600879
|
0.130x |
|
NEW ORIENTAL EDU.+TECH.G.
F:N1U0
|
-0.002x |
|
TPG Inc
NASDAQ:TPG
|
0.047x |
|
NISSAN MOTOR SP. ADR/2
F:NISE
|
N/A |
|
New Oriental Education & Technology
NYSE:EDU
|
-0.002x |
|
NKT A/S
CO:NKT
|
0.036x |
|
National Aluminium Company Limited
NSE:NATIONALUM
|
0.126x |
Annual Cash Flow Conversion Efficiency for ICON Public Limited Company (2016–2024)
The table below shows the annual cash flow conversion efficiency of ICON Public Limited Company from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of ICON Public Limited Company.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €9.52 Billion ≈ $11.13 Billion |
€1.29 Billion ≈ $1.50 Billion |
0.135x | +88.75% |
| 2023-12-31 | €9.24 Billion ≈ $10.80 Billion |
€661.47 Million ≈ $773.33 Million |
0.072x | +8.90% |
| 2022-12-31 | €8.57 Billion ≈ $10.02 Billion |
€563.32 Million ≈ $658.57 Million |
0.066x | -36.05% |
| 2021-12-31 | €8.07 Billion ≈ $9.43 Billion |
€829.14 Million ≈ $969.35 Million |
0.103x | -66.52% |
| 2020-12-31 | €1.85 Billion ≈ $2.16 Billion |
€568.03 Million ≈ $664.09 Million |
0.307x | +20.41% |
| 2019-12-31 | €1.62 Billion ≈ $1.89 Billion |
€412.54 Million ≈ $482.30 Million |
0.255x | +28.53% |
| 2018-12-31 | €1.35 Billion ≈ $1.58 Billion |
€268.64 Million ≈ $314.07 Million |
0.198x | -38.33% |
| 2017-12-31 | €1.19 Billion ≈ $1.39 Billion |
€383.08 Million ≈ $447.86 Million |
0.322x | +17.29% |
| 2016-12-31 | €945.17 Million ≈ $1.11 Billion |
€259.20 Million ≈ $303.04 Million |
0.274x | -- |
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more